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2 
Abstract 24 
There is a complex interplay between cognition and gait in older people, with declines in gait 25 
speed coexisting with, or preceding cognitive decline. Omega-3 fatty acids, B vitamins, vitamin 26 
E, phosphatidylserine, and Ginkgo Biloba show promise in preserving mobility and cognitive 27 
function in older adults. Exercise benefits mobility and there is evidence suggesting positive 28 
interactions between exercise and omega-3 fatty acids on physical and cognitive function in older 29 
adults. Non-frail or pre-frail females aged ≥60 years are included in a randomized placebo 30 
controlled study. Intervention groups are: high DHA multi-nutrient supplement and exercise, 31 
placebo supplement and exercise, high DHA multi-nutrient supplement, and placebo supplement. 32 
Dietary supplementation is 24 weeks. The exercise intervention, two cycle ergometer classes per 33 
week, is for the final 12 weeks. The primary outcome is habitual walking speed, secondary 34 
outcomes include gait variables under single and dual task, five times sit to stand, verbal and 35 
spatial memory, executive function, interference control and health related quality of life. Blood 36 
fatty acids, serum homocysteine, dietary intake, physical activity, and verbal intelligence are 37 
measured to assess compliance and control for confounding factors. The study is registered at 38 
www.clinicaltrials.gov (NCT03228550).  39 
Keywords: Docosahexaenoic acid1, Memory2, B Vitamins3, Physical Activity4, Gait5, Aging6  40 
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1 List of Abbreviations: Dual task (DT), Template for Intervention Description and Replication 
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Learning Test (RAVLT), Enzyme-linked immunosorbent assay (ELISA), Food frequency 
questionnaire (FFQ), Community health activities program for seniors (CHAMPS), Short form 36 
questionnaire (SF-36) 
 
 
 
3 
1 Introduction 45 
In Europe the proportion of adults aged ≥65 years is expected to rise from 16.1 to 22% by 46 
2031[1].  Currently 23% of the total global burden of disease is attributable to disorders in people 47 
aged 60 years and older [2].  The trend towards an ageing population and the expected continual 48 
rise in age related disease will have profound implications for the health care systems for decades 49 
to come. The UK spent £9.3 billion on health and social care for older adults in 2010 and this is 50 
projected to increase to £12.7 billion by 2022 [3].  51 
Mobility and cognitive function are two key functional domains upon which preventative 52 
strategies should be targeted towards in older adults [4].  Mobility impairments are associated 53 
with reduced health related quality of life [5], and cognitive decline is associated with both 54 
increased risk for future inability to perform instrumental activities of daily living and loss of 55 
independence in older adults [6].  It is normal to observe some decline in mobility and cognitive 56 
function with age [7, 8], thus preventative interventions are aimed at reducing the trajectory of 57 
this decline and promoting what is referred to as “healthy” or “successful” ageing[9].  Some of 58 
the key domains to consider to achieve healthy ageing are autonomy in activities of daily living, 59 
wellbeing, good quality of life, high social participation, only mild cognitive or functional 60 
impairment, and little or no physical disability [10]. 61 
Mobility limitations increase with advancing age and are often a sign of further functional decline 62 
[11].  Habitual and fast walking speeds are both examples of widely used performance based 63 
indicators of mobility [12, 13].  Gait speed is an established clinically relevant marker in older 64 
adults, it is associated with mortality[14], risk of falls[13] and functional capacity[15]. In addition 65 
to its use as a measure of physical functioning, there is now strong evidence to suggest a 66 
relationship between cognitive function and gait.  Changes in several gait parameters including 67 
speed, variability, cadence, stride length, and time spent in the double support phase coexist with 68 
or precede onset of cognitive decline in older adults [16].  Interventions that can target cognition 69 
improve mobility [17, 18], which can translate into increased survival rate [19]. The role of 70 
cognitive function in relation to walking is increasingly important in older adults when they are 71 
required to conduct a simultaneous secondary task (dual-task paradigm). Inability to maintain a 72 
conversation while walking is a strong predictor of falls in older adults[20]. Consequently dual-73 
task (DT) gait protocols have become an established way to assess the relationship between 74 
cognition and gait [21]. 75 
Most of the pharmacological approaches used in age related health conditions have been met with 76 
limited success, and this is likely due to the multifactorial aetiology underlying these conditions, 77 
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for example varying physical and neurological pathologies as well as factors such as 78 
inflammation, metabolism, and genetics [22].  Development of lifestyle interventions to reduce 79 
the burden of age related health conditions would be highly advantageous considering the poor 80 
efficacy of the current pharmaceutical options [23].  Dietary compounds and exercise have been 81 
shown to separately act on a broad spectrum of health outcomes in older adults including gait 82 
speed, cognition and muscle strength and function [17, 24, 25]. The capacity to act on multiple 83 
outcomes makes these lifestyle interventions particularly valuable in the prevention of age related 84 
cognitive and physical impairments. Some of the lifestyle interventions that have shown potential 85 
promise in combatting age related declines in mobility and cognition include aerobic exercise and 86 
dietary compounds such omega-3 polyunsaturated fatty acids (omega-3 PUFAs), vitamin E, 87 
phosphatidylserine (PS), B vitamins, and Ginkgo Biloba [17, 26-29]. There is a growing 88 
awareness of the importance of taking a more holistic approach to research into nutrition and 89 
brain ageing, exploring potential synergies between nutrients and how these may influence both 90 
cognition and mobility [30]. For example, work in our laboratory shows that the high DHA multi-91 
nutrient dietary supplement used in this protocol, which contains docosahexaenoic acid (DHA), 92 
vitamin E, phosphatidylserine (PS), B vitamins, and Ginkgo Biloba increases habitual gait speed, 93 
verbal memory, and processing speed in older women versus placebo [17]. Similarly, a multi-94 
nutrient supplements containing omega-3 polyunsaturated fatty acids (PUFAs), phospholipids, B 95 
vitamins, and antioxidants show promise in those with mild Alzheimer’s disease [31, 32]. 96 
However, despite showing promise separately, there is currently no evidence available as to the 97 
effects on mobility and cognition when combining these dietary factors with an exercise 98 
intervention.  99 
There is mounting evidence that the omega-3 PUFAs eicosapentaenoic acid (EPA) and DHA may 100 
play a role in the prevention of age related cognitive decline [33] and mobility impairments [34], 101 
through mechanism related to cell signalling, inflammation, enhancing neurogenesis, promoting 102 
neuronal survival and increasing muscle protein synthesis [33, 35-37]. DHA is the predominant 103 
omega-3 PUFA in the human brain [38], where it is concentrated in the phospholipid membranes, 104 
particularly at the synapses[39]. Two recent trials have reported that DHA supplementation may 105 
slow progression of brain atrophy and preserve cognitive function in older adults [40]. Control of 106 
gait requires the appropriate integration of information from motor, sensory and cognitive 107 
systems, and cognitive processes including executive function, attention and processing speed 108 
share the strongest associations with habitual and DT gait outcomes [41, 42]. Several studies have 109 
suggested that omega-3 PUFAs may benefit these cognitive processes. For example, omega-3 110 
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PUFA supplementation is associated with improved attention, verbal memory and immediate 111 
recall [43, 44], as well as executive function and processing speed [17, 45, 46] in older adults.  112 
PS is a major phospholipid class that accounts for 13-15% of the human cerebral cortex. PS is 113 
essential for the activation of key signalling pathways that stimulate neuronal survival, neurite 114 
growth and synaptogenesis [47]. There is currently limited data on supplementation trials with 115 
PS; however, a small trial in older adults showed positive effects of 300 mg  per day PS 116 
supplementation for twelve weeks on memory, recall, executive functions, and mental flexibility 117 
[48]. Since PS contains high levels of DHA it is unclear whether the benefits from PS 118 
supplementation are due to intact PS or the release of DHA following hydrolysis [47].  119 
Higher levels of vitamin E (α-tocopherol) are associated with lower risk for cognitive impairment 120 
in older adults [49]; however, clinical trials have shown limited benefit of supplementation[50]. 121 
Vitamin E plays an important role in protecting cell membranes from damage by free radicals, 122 
and protects the highly unstable polyunsaturated fatty acids, particularly DHA, from lipid 123 
peroxidation [51], and it may be that beneficial effects  of vitamin E are due to the role it plays in 124 
protecting DHA in membranes. 125 
B12 and folic acid act as cofactors for the methylation of homocysteine to methionine [52].  High 126 
homocysteine levels are associated with physical frailty [53], cognitive decline [54], and 127 
cardiovascular disease [55]. Dietary supplementation trials with B vitamins have shown mixed 128 
results on cognitive function and physical outcomes [56, 57], with evidence suggesting those with 129 
higher homocysteine levels are most responsive [58-60]. However, the effects may be dependent 130 
on omega-3 PUFAs, since B vitamin supplementation in those with higher baseline plasma 131 
omega-3 PUFAs resulted in a significant decrease in rates of brain atrophy versus placebo [61]. 132 
The mechanisms underpinning this interaction are currently not well understood, however 133 
homocysteine has been shown to impact phospholipid and DHA metabolism by inhibiting 134 
methylation reactions that convert phosphatidylethanolamine enriched with DHA to 135 
phosphatidylcholine [62].  Furthermore DHA has been shown to influence gene expression of 136 
enzymes that control homocysteine metabolism [63]. 137 
Ginkgo Biloba is one of the most widely used and studied herbal extracts for cognitive 138 
impairment and dementia in older adults.  Results from clinical studies have largely yielded 139 
inconsistent results, however a recent meta-analysis indicates that supplementation with 240mg 140 
standardized extract per day in patients with dementia and cognitive impairment can slow 141 
cognitive decline over 22 to 26 weeks [26]. 142 
Regular physical activity and exercise are promoted by the World Health Organization (WHO) to 143 
improve functional health and reduce the risk for non-communicable disease (WHO, 2010). 144 
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Exercise promotes adaptations to physiological systems that can in turn influence factors 145 
associated with healthy ageing.  This includes neuromuscular adaptations that influence strength 146 
and the ability to coordinate movements [65], improvements to cardiorespiratory fitness [66] and 147 
preservation of the brain [67]. Aerobic training has shown promise with regards to healthy ageing 148 
due to its ability to act across a broad range of health related factors including both the physical 149 
and cognitive domains [68-70]. Of particular importance to the older adult, aerobic exercise 150 
interventions are shown to influence processing speed and executive function [71]. Cycling is a 151 
form of aerobic exercise that can benefit muscle strength, cardiopulmonary fitness, balance and 152 
proprioception in older adults [27, 72].  Furthermore cycling may be preferential for older adults 153 
as it is non-weight bearing, has a low impact on joints and has been found to be suitable and 154 
beneficial for those with joint pain [73]. 155 
Recent evidence suggests multi-domain approaches, such as combining omega-3 PUFAs with 156 
exercise may provide additional benefits to both cognitive function and physical ability when 157 
compared to either approach alone. For example, a recent multi-domain intervention, consisting 158 
of omega-3 PUFA supplementation, nutritional and exercise counselling and cognitive training 159 
was more effective than either omega-3 PUFA supplementation alone or placebo/usual care in 160 
limiting long-term physical activity declines [74]. Similarly, a trial of older adults with mild 161 
cognitive impairment compared the effects of daily supplementation with omega-3 PUFAs alone 162 
or in combination with twice weekly stationary cycle training and a program of cognitive 163 
stimulation for eight months [75]. The combined intervention led to an enhanced reduction of 164 
brain atrophy in grey matter regions compared to supplementation alone. Interestingly, this effect 165 
was associated with serum homocysteine levels, suggesting a potential import interaction with B 166 
vitamin status. A further recent trial in older adults found that combining daily omega-3 PUFA 167 
supplementation with resistance training over an 18 week period provided an additional benefit to 168 
muscle strength (maximal isometric torque) in knee extensor muscles compared with the exercise 169 
alone, although this effect was only observed in the female participants [76]. Therefore, since this 170 
observation suggests that women are more amenable to the effects of omega-3 PUFA 171 
supplementation and exercise, and females have been shown to have greater compliance to 172 
exercise interventions[77], the study will restrict participation to female volunteers only. The 173 
mechanisms underpinning the observed interaction between omega-3 PUFAs and exercise are not 174 
clear; however, both exercise and omega-3 PUFAs have been shown to share a number of similar 175 
effects including increasing neurogenesis and neural plasticity, muscle protein synthesis and 176 
reducing inflammation and homocysteine levels [37, 75, 78-81]. Furthermore it also cannot be 177 
determined at this stage whether any interaction between the two interventions is additive or 178 
synergistic. Overall, these results suggest that the addition of dietary supplementation with 179 
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omega-3 PUFA to exercise may enhance training adaptations in the older population, which is 180 
important as older adults often display an attenuated response to exercise or require more regular 181 
training stimulus to maintain muscle compared to younger adults [82, 83].     182 
The present study extends our previous research by determining whether the preliminary 183 
observations of positive effects of supplementation on cognition and mobility can be replicated 184 
[17] and investigating whether the addition of an exercise intervention enhances these effects.  By 185 
using a unique blend of nutrients on their own and in combination with aerobic exercise, this 186 
study will provide a novel insight into the efficacy of two promising lifestyle interventions, using 187 
outcome measures that encapsulate healthy ageing. It is hypothesized that both the DHA multi-188 
nutrient supplement and the aerobic exercise will improve mobility and cognitive function versus 189 
the placebo in older women and that combining the two interventions will produce a greater 190 
benefit compared to each separately.    191 
2 Research Aims  192 
The aims of this semi-blinded randomised control trial on the effects a high DHA multi-nutrient 193 
supplement alone and in combination with aerobic exercise in women aged 60 years and older are 194 
as follows.  195 
 To investigate the effects of each intervention in isolation and in combination on mobility, 196 
cognitive function and health related quality of life, to establish whether there are 197 
treatment effects as well as any additive or synergistic benefits. 198 
 To investigate whether there are relationships between circulating DHA and serum 199 
homocysteine with mobility and cognitive outcomes. 200 
3 METHODS AND ANALYSIS   201 
3.1 Design and Setting 202 
The study is a randomised semi-blinded, placebo controlled trial in females aged 60 years and 203 
above.  The study is designed to examine the effects of a high DHA multi-nutrient dietary 204 
supplement and aerobic exercise, both on their own and in combination, on outcomes related to 205 
mobility and cognitive function. All measurements and data collection, as well as the aerobic 206 
exercise intervention take place in the same study site (Bournemouth University, U.K.), with 207 
participants being instructed to consume the dietary supplement at home.  208 
3.2 Blinding Randomisation and Allocation 209 
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The dietary supplements are packed into identical containers and coded by the Principal 210 
Investigator, who has no involvement in the data collection. Omega-3 PUFA capsules have a 211 
distinct odour, therefore a small amount of fish oil is added to the placebo capsules to help maintain 212 
blinding. Exercise class allocation is communicated through letters which are coded by the Principal 213 
Investigator and distributed in sealed envelopes. A stratified block randomization design is 214 
followed [84] with stratification based on frailty classification of non-frail or pre-frail (see section 215 
3.5), followed by permuted block randomization.  Randomization is achieved by creating a 216 
computer-generated list of numbers consisting of four blocks for each strata referred to without 217 
specification of intervention group (e.g., A, B, C and D). The list is generated and stored by the 218 
Principal Investigator, who is not involved in the data collection. Due to the nature of the exercise 219 
intervention participants are only blinded to the dietary intervention; however, the experimenters 220 
are blinded to the group allocations. 221 
In the event of a severe adverse effect being reported by a participant the Principal Investigator 222 
will be able to gain access to the participant allocation so that appropriate action can be taken, 223 
whilst maintaining the blinding of those involved with data collection and analysis.   224 
3.3 Participant Recruitment and Eligibility Criteria  225 
Participants are recruited through public advertisements and public engagements in Bournemouth, 226 
U.K. The public advertisements include a brief study description as well as the contact details for 227 
the research team. Interested individuals receive a participant information document including the 228 
design, procedure, benefits, and risks of the trial. Before any data is collected all participants 229 
provide signed written informed consent forms.  230 
Females aged 60 years and above are recruited according to the following inclusion criteria: (1) 231 
able to walk at least 50 m unaided, (2) classified as non-frail or pre-frail and community dwelling.  232 
Exclusion criteria are: (1) vestibular impairments, (2) diagnosed neurological disorder, (3) 233 
cognitive impairment (Mini Mental Status Examination score of 24 or below), (4) lower limb 234 
surgery, (5) seafood allergy, (6) regular consumption of multivitamin or fish oil supplements 235 
within six months prior to baseline measurements, and (6) previously received advice from a 236 
health care professional not to undertake strenuous exercise.  237 
3.4 Interventions 238 
The study interventions are described in detail according to the Template for Intervention 239 
Description and Replication (TIDieR) guidelines in table 1. 240 
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Dietary Supplement 241 
All participants consume four capsules per day of their respective dietary supplement for the 24 242 
weeks of the study, and are instructed to take them with their main meal of the day. The total 243 
daily dose from the active capsules contains 1000 mg DHA, 160 mg EPA, 20 µg vitamin B12, 1 244 
mg folic acid, 124 mg PS, 240 mg ginkgo biloba standardized leaf extract and 20 mg vitamin E. 245 
The duration of 24 weeks and dose of supplementation has previously been shown to increase 246 
tissue omega-3 PUFA levels and induce improvements in cognition and mobility [17]. The 247 
placebo capsules contain an isocaloric oil blend typical of the U.K. diet including a small amount 248 
of fish oil. The fatty acid content of the active and placebo capsules is analysed by gas 249 
chromatography coupled to flame ionization detector, as detailed below. Active and placebo 250 
capsules are kindly provided by Efamol Ltd.  Compliance to the dietary supplement is measured 251 
by changes in DHA levels compared to baseline, with a change of 5% being the threshold for 252 
compliance [85], counting returned pills at 12 and 24 weeks, and exit questionnaire. A systematic 253 
review concluded that the potential for adverse events with omega-3 PUFA supplementation 254 
should be considered mild-moderate at worst and unlikely to be of clinical significance [86]. 255 
Exercise Training 256 
The exercise intervention consists of two group sessions per week on a Spinner Fit stationary 257 
bike, led by a qualified instructor. For the first six weeks classes last 30 min and in the second six 258 
weeks session length increases to 45 min. All sessions consist of a 5 min warm up and cool down 259 
at 7-8 on the Borg scale of rate of perceived exertion [87].  During the main part of the sessions 260 
participants maintain intensity between 12 to 14 on the Borg scale. These intensity levels on the 261 
Borg scale are considered moderate to vigorous, and similar intensity levels produce positive 262 
responses in this population [88, 89]. Older adults are typically heterogeneous in terms of their 263 
aerobic fitness [90] therefore using the Borg scale allows each participant to exercise at their own 264 
level, whilst still being encouraged to maintain the moderate-vigorous intensity levels that are 265 
desired. Compliance to the exercise intervention is monitored by recording attendances by each 266 
participant and calculated as the percentage of classes attended, with 70% being the threshold for 267 
compliance [91]. 268 
 269 
3.5 Screening 270 
All participants are screened to assess frailty status, according to the criteria developed by Fried 271 
and co-workers [92]. The criteria includes low muscle strength, self-reported exhaustion, slow 272 
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gait speed, low levels of physical activity, and unintentional weight loss, as shown in Table 2. A 273 
score of zero out of the five indicates non-frail, one or two pre-frail, and three or above frail. As 274 
well as a screening procedure non-frail and pre-frail status is used as a prognostic factor in the 275 
randomisation.   276 
 277 
The Mini Mental State Examination (MMSE) is performed to exclude participants with 278 
undiagnosed cognitive impairment [93]. The test is performed according to British Psychology 279 
Society guidelines (2010) and not used for diagnostic purposes, with individual results not 280 
disclosed. Participants who score ≤ 24 are excluded from the trial. 281 
3.6 Demographic Information 282 
Information on the age, height, weight, verbal intelligence, and medication use are collected from 283 
each participant. Information on medications is self-reported, with both type and number of 284 
medications recorded.  The national adult reading test (NART) is used to assess verbal 285 
intelligence[95]. The test requires participants to read aloud 50 pre-prepared words, with a score 286 
being calculated based on the number of correct pronunciations. Minor variations from the 287 
pronunciations are not penalised as the aim of the test is to assess familiarity with the words 288 
rather than exact pronunciation.      289 
3.7 Outcomes 290 
All measurements are performed at baseline and at the end of the study. The primary and 291 
secondary outcomes are listed in Table 3.  292 
3.7.1 Gait Analysis 293 
Gait speed, stride length variability, stride length, cadence, and double support phase percentage 294 
are measured using Opal inertial sensors and analysed using Mobility Lab™ software version 3.1 295 
(APDM Inc, http://apdm.com). Sensors are placed on the feet over the shoes according to the 296 
manufacturers’ instructions.  Acceleration and deceleration phases of the gait cycle are removed 297 
from the analysis, and each test will take place over 13 m. Each tested condition is repeated five 298 
successful times to obtain representative samples and the means of the trials are used for data 299 
analysis for habitual and dual task gait with the maximum gait speed value being used for the fast 300 
walking condition. 301 
Participants are assessed under three gait conditions: habitual walking (HW), fast walking (FW), 302 
and DT walking. Participants walk at a normal comfortable pace for the HW and DT protocols 303 
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and as fast as possible for the FW protocol. During the DT protocol participants count backwards 304 
in integers of three from a randomly generated three digit number given three seconds before 305 
commencement of the task. Although there is currently no standardised secondary task for dual 306 
task gait protocols a backwards counting task in integers of three has been used in several prior 307 
studies in similar demographics [21, 96-98]. Participants are not instructed to prioritize either 308 
walking or counting backwards during the DT condition. The use of gait speed as a clinical 309 
measure in older adults is well established due to its association with physical functioning, falls, 310 
disability, and mortality [14, 99]. The relative dual-task costs (DTC) as percentage of loss relative 311 
to the single-task performance is calculated based on the formula DTC [%] = 100* (single-task 312 
score - dual-task score)/ single-task score [100]. 313 
 314 
3.7.2 Five Times Sit to Stand  315 
The five times sit to stand tests is a valid measure of dynamic balance and functional mobility in 316 
older adults that is commonly used in studies in geriatric populations [101].  To perform the five 317 
times sit to stand participants start off seated on a standard chair 44 cm in height from the ground, 318 
with arms folded across their chest and back against the chair. They stand up fully from the chair 319 
and sit back down again five times, whilst keeping their arms in the same position. This task is 320 
assessed by timing participants from the prompt to start until they reached a seated position on the 321 
fifth repetition. 322 
 323 
3.7.3 Cognitive Function 324 
A Stroop test is used to assess interference control [102] using Open Sesame version 3.1.1. 325 
software [103].  During this task a fixation point appears on screen for 500 ms followed by the 326 
presentation of the names of one of four colours: blue, red, green, and white.  These words are 327 
presented in four different font colours varying between blue, red, green, and white. Participants 328 
are instructed to identify, as quickly as possible without sacrificing accuracy, the colour of the 329 
text rather than the word displayed on screen and press a designated key on the keyboard, 330 
highlighted using coloured stickers. The test comprises 144 trials with half of trials having the 331 
text and colour match (congruent trials) and half being a non-match (non-congruent trials). 332 
Interference control is defined as the difference between the mean time taken to respond to the 333 
congruent and non-congruent trials. Reaction times that are plus or minus 2.5 times the median 334 
absolute deviation are excluded as anomalous results [104].       335 
Spatial memory is assessed using a computerized task, run on Open Sesame version 3.1.1. 336 
software, based upon work conducted by Nagamatsu, L. S. et al. (2013).  The task requires 337 
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participants to recall the spatial location of dots presented on a screen.  Each trial comprises a 338 
presentation and a test phase. In the presentation phase three dots appear at randomly allocated 339 
locations for 500 m, this is followed by a fixation cross which appears for 3 s.  After the retention 340 
interval the test phase comprises presentation of a single red test dot on the screen, this can either 341 
is in the same location as one of the previous black dots (match) or in a different location (non-342 
match).  Participants are asked to identify if the red test dot was a match or a non-match to any of 343 
the prior black dots by pressing an assigned key on the keyboard (“y” = match; “n” = non-match).  344 
There is no time limit for the participants to respond as the focus of the task is on response 345 
accuracy.  The task consists of ten practice trials, followed by sixty recorded trials.  Thirty of the 346 
trials are matched and 30 are non-matched.  The thirty non-matched are evenly split in three 347 
degrees of difficulty, whereby they are placed at two (near), four (medium) and eight (far) degrees 348 
visual angle.  These angles were calculated based on the participant sitting 50 cm from the screen.  349 
Accuracy for the task is recorded as the percentage of correct answers. 350 
The Rey’s Auditory Verbal Learning Test (RAVLT) is an established cognitive testing tool that 351 
requires participants to recall a list of 15 pre-set words and is used for assessing verbal 352 
memory[105]. 353 
A trail making task is used to assess executive function[106].  In this task participants are asked to 354 
draw lines between targets on a piece of paper, as rapidly as possible, in a grid of seven by seven 355 
squares.  There are four different conditions for the task: (1) a numbers condition where targets go 356 
from one to 49 (numbers), (2) a letters condition where the targets go from A to Z (letters), (3) a 357 
condition where participants alternate between numbers (1-25) and letters (A-X), (numbers-358 
letters), and finally, (4) a condition alternating between letters (A-Y) and numbers (1-24) (letters-359 
numbers).  Scores are recorded as the total number of correct connections within the time limit. 360 
 361 
3.7.4 Whole Blood Fatty Acids Analysis 362 
Whole blood pin-prick samples from non-fasted participants are collected on Silica gel loaded 363 
filter paper (Whatmantm) pre-treated with 2,6-di-tert-butyl-p-cresol (butylated hydroxytoluene, 364 
BHT).  Samples are collected and processed as described previously [17]. Pre- and post-365 
intervention fatty acid levels are compared to assess compliance and response to supplementation.  366 
3.7.5 Serum Homocysteine 367 
A non-fasted venous blood sample will be drawn to assess serum homocysteine. Samples are 368 
collected using a Vacutainer Safety-Lok collection set fitted with a 10 mL serum collection tube 369 
(Becton, Dickinson and Company).  Each blood sample is allowed to clot and then immediately 370 
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centrifuged at 2000 x g for 10 minutes at 4⁰C and the serum extracted[107]. Serum samples are 371 
stored at -80C and analysed within three months[108]. Serum homocysteine levels are measured 372 
using a competitive enzyme-linked immunosorbent assay (ELISA) kit (Cell Biolabs Inc.). 373 
 374 
3.7.6 Dietary Intake and Physical Activity Levels  375 
Differences in diet and physical activity habits between the groups, as well as changes in these 376 
aspects within groups have the potential to influence the outcomes of the study, for example 377 
increasing protein intake has been shown to maintain lean mass and physical function in older 378 
adults [109].  Although participants are asked to maintain their current diet and lifestyle habits, 379 
these aspects are also monitored at baseline and completion of the study. 380 
Three day estimated food diaries are used to assess dietary intake. Written instructions are 381 
provided alongside the food diaries. Participants record details of all foods and beverages 382 
consumed at the time of consumption. They are asked to include brand names, cooking and 383 
preparation methods and an accurate description of the portion size using standard household 384 
measures or natural unit sizes. Results are analysed using computer dietary analysis software and 385 
results expressed in grams or kilocalories for macronutrients and energy, respectively. A 386 
previously validated seventeen item food frequency questionnaire (FFQ) is used to specifically 387 
quantify omega-3 PUFA intake [110].  388 
The community health activities program for seniors (CHAMPS) questionnaire is used to assess 389 
physical activity levels [111].  The CHAMPS questionnaire is a validated and reliable measure of 390 
physical activity in older adults, which covers a broad range of activities and has been shown to 391 
be sensitive to change over six months [111]. 392 
3.8 Health Related Quality of Life  393 
The short form (SF) 36 health questionnaire has been shown to be a practical and valid tool for 394 
assessing health status [112].  The questionnaire is issued at baseline and end of the study. 395 
Answers are divided into sub-categories: vitality, physical functioning, bodily pain, general health 396 
perceptions, physical role functioning, emotional role functioning, social role functioning and 397 
mental health. Each sub-category is scored on a scale of zero to one hundred with a higher score 398 
indicating a more positive health status [113].  399 
3.9 Data Management  400 
The chief investigator will be responsible for all data collection, and has received training on all 401 
collection and analysis techniques.  402 
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All data from participants will be assigned to a number to prevent results being tracked back to an 403 
individual. The chief investigator will be responsible for all the storing and handling of data. 404 
Digital data from the study will be stored on a password protected Bournemouth University staff 405 
account only accessible by the research team. All paperwork including completed consent forms, 406 
lifestyle questionnaires and raw data outputs will be locked in a filing system within a secure 407 
building at Bournemouth University (U.K). Results from the study will be anonymised with 408 
participants being assigned numbers. All data relating to the trial will be archived for 5 years after 409 
the conclusion of the study 410 
3.10 Sample Size 411 
Sample size was determined based on the primary outcome of habitual walking speed. Using an 412 
effect size based on previously published values, minimally significant changes in gait speed were 413 
0.03 m/s and 0.05 m/s with substantial changes at 0.08 m/s[114].  The sample size calculation is 414 
based on a difference of 0.08 m/sec with a power of 0.8 and α of 0.05 (two-tailed). A minimum 415 
sample size of 25 participants per group is required to detect an effect size d of 0.8 between 416 
experimental groups and the control. An overall recruitment target of 120 participants, 30 per 417 
group has been set to allow for drop-outs over the 24 weeks of the trial. 418 
3.11 Statistical analysis  419 
Data analysis is performed at the conclusion of the study and includes data collected at baseline 420 
and following the 24 week intervention. Data is tested for normal distribution using Shapiro-Wilk 421 
test and Q-Q-plots.  If data are normally distributed the following statistical methods will be used;  422 
however, for data not fulfilling assumptions of normal distribution the non-parametric equivalent 423 
will be substituted. A 2 × 2-ANOVA test will be used to compare the two interventions over time 424 
(from pre- to post-measurement) on changes on the dependent variables. Effect size calculation 425 
(η² (Eta squared)) will also be calculated. Participants' demographic and health information, such 426 
as age and NART score, in addition to changes in serum homocysteine and whole-blood PUFAs 427 
will be examined in relation to the outcome measures to interpret the results in context. Analysis 428 
will be carried out on an intention-to-treat basis and include any participants who decide to 429 
discontinue treatment, but complete the intervention period and assessment at 24 weeks.  430 
Associations between serum homocysteine, whole-blood DHA levels, and measures of mobility 431 
and cognition will be examined at baseline using Pearson’s partial correlations controlling for 432 
age. NART score will also be included as a covariate in preliminary analysis. Correlation data 433 
will be examined to ensure assumptions are not violated. In all analyses P<0.05 will be 434 
considered significant. 435 
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Baseline and 24 week results from the diet and physical activity assessments will be compared 436 
within groups, using paired T-tests, to determine whether participants have made any significant 437 
changes to their diet and physical activity habits during the study intervention. Diet and physical 438 
activity data, along with data collected on medication use will be examined so that interpretation 439 
of results can be made within the context of potential differences of other lifestyle related factors.  440 
3.12 Stepwise Procedure 441 
The stages of the study procedure are illustrated in Figure 1. Ethical approval for the study was 442 
granted on 23/06/2016 with data collection commencing on 27/02/2017.  Data collection is 443 
expected to be completed by 07/10/2018. Measurements are undertaken at baseline and following 444 
the 24 week intervention period. A mid-study appointment is given at 12 weeks to collect unused 445 
dietary supplement capsules to monitor compliance, and to issue participants with the dietary 446 
supplements required for the remainder of the trial. The baseline measurements consist of the 447 
screening process assessing frailty and cognitive impairment, if eligible this will be followed by 448 
the main testing battery, which includes the tests of mobility and cognitive function outlined 449 
above. Upon completion of the data collection sessions at baseline and 24 weeks participants are 450 
issued with a food diary, FFQ, CHAMPS and SF-36 questionnaires. These are fully explained by 451 
a member of the research team and written instructions given, they will then be asked to fill these 452 
out at home over the next week and return.     453 
Participants’ begin their dietary supplementation intervention on the same day their blood sample 454 
is taken. Initially participants are given 12 weeks supply of their respective supplements, they are 455 
asked to bring in remaining capsules at the 12 week point, before issuing them with the second 456 
batch of supplements to be taken until the end of the study. The week following the 12 week data 457 
collection the aerobic exercise intervention commences, this takes place twice a week for the final 458 
12 weeks of the trial.   459 
Adherence to exercise interventions can be problematic, an issue that has consistently been raised 460 
in the literature [91, 115, 116].To maximise adherence, the exercise intervention involves a 461 
supervised programme, as these have been shown to be associated with higher adherence 462 
rates[116]. Furthermore, the exercise sessions are scheduled at convenient times for participants, 463 
and participants are given a phone call every two weeks to provide ongoing support and 464 
encourage adherence to the exercise intervention and compliance with the dietary 465 
supplementation. 466 
3.13 Monitoring  467 
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The data and safety monitoring will be performed by the research team. The team will meet once 468 
per month, to discuss any issue and check on the conduction of the study. Adverse events as 469 
defined by Clinicaltrials.gov [117] will be monitored by participant self-reporting and exit 470 
questionnaire. Adverse events will be reported by the Principal investigator to the institutional 471 
research representative and sponsor. There is no independent data safety and monitoring board 472 
made for this study due to the anticipated low risk nature of the intervention. There are no plans 473 
for interim analyses due to the relatively low sample size. 474 
3.14 Patient and Public Involvement  475 
The primary and secondary outcomes for the study were chosen based on the latest 476 
recommendations for clinically relevant measures in intervention trials on healthy ageing [9]. In 477 
the design phase of the study older women without cognitive or mobility impairment were invited 478 
to attend testing sessions, where they were asked to complete the cognitive testing and DT gait 479 
protocols. These sessions allowed the research team to determine whether there were any floor or 480 
ceiling effects of the testing. This meant that changes to the difficulty of the testing could be made 481 
to ensure the validity of the testing as well as ensuring the safety and comfort of the participants. 482 
Furthermore participants were invited to give their feedback during these sessions on how the 483 
tasks were presented, to ensure that all tests had clear instructions and were well understood. 484 
Upon completion of the trial all participants will receive a letter giving a full summary of the 485 
study and the results.  486 
4 ETHICS AND DISSEMINATION  487 
Ethical approval for the study procedure has been granted by the Bournemouth University 488 
Science Technology and Health research ethics panel (Ethics ID 10788) and conforms to the 489 
declaration of Helsinki and guidelines for Good Clinical Practice.  The trial protocol follows the 490 
Consolidated Standards of Reporting Trials (CONSORT) statement on randomised trials of non-491 
pharmacological treatment [118] and the Standard Protocol Items: Recommendations for 492 
Interventional Trials (SPIRIT) guidelines [119]. In the event of any important protocol 493 
modifications, all investigators and trial participants will be notified, amendments will be made to 494 
the clinical trials registry and a resubmission of the protocol will be made to the ethics panel. The 495 
results of this study will be presented in a PhD thesis, at scientific conferences and submitted to 496 
peer-reviewed journals. No data is collected until fully informed consent is given by participants. 497 
Interested parties who meet the eligibility criteria are sent a copy of the participant information 498 
sheet, which contains all the necessary information required to take part in the study, participants 499 
are given an minimum of 24 hours before being asked to give their consent and are encouraged to 500 
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contact a member of the research team if they have any questions or concerns regarding 501 
participation. Following completion of the trial all participants who received the placebo 502 
supplement during the study will be offered 24 weeks supply of the active supplement, 503 
furthermore all participants will be offered a written summary of the results. 504 
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Figure 1. Participant flow through the study. 835 
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Table 1 Description of study intervention based on the Template for Intervention Description and 856 
Replication (TIDieR) checklist[120]. 857 
Item Experimental Group Experimental Group Experimental Group Control Group 
1. Group DHA Multi-nutrient 
Supplement and Exercise  
Placebo Supplement and 
Exercise  
DHA Multi-nutrient 
Supplement  
Placebo 
Supplement  
2. Why? A high DHA multi-nutrient supplement formula has previously been shown to improve habitual gait 
speed, verbal memory and processing speed in older women [17].  Cycle ergometer training is a form of 
exercise that can benefit muscle strength and cardiopulmonary fitness in older adults [27].  There is 
some evidence for a positive interaction between omega-3 PUFA and exercise in older women on 
muscle strength and cognitive function [121, 122] 
3. What 
materials? 
Participants receive containers with DHA multi-nutrient supplement capsules and instructions on daily 
intake. 
Exercise classes take place in a sport studio on spinning cycle ergometers. 
4. What 
procedure? 
Participants take four capsules per day of their allotted supplement, alongside their main meal of the day. 
Those allotted to the exercise intervention attend two classes per week for the final 12 weeks of the 
study.  Classes will initially last 30 min for the first 6 weeks and then increase to 45 min for the final 6 
weeks. 
5. Who 
provides?  
Principal Investigator issues participants with their dietary supplements. 
Exercise classes are carried out by a qualified instructor. 
6. How? For the dietary supplements, all groups receive initial instructions about intake, duration and dosage by 
the Principal Investigator. 
The exercise classes will be performed in small groups. 
7. Where? The participants take the dietary supplements at home. The aerobic exercise classes take place in sports 
studios at Bournemouth University U.K. 
8. When and 
how much? 
For 24 weeks participants will take four capsules per day of their allotted supplement.  After 12 weeks 
the participants will start their exercise classes, twice per week for the final 12 weeks of the study. 
9. Tailoring Participants are told to maintain a specific revolution per minute on the cycle ergometer. They self-select 
a resistance to allow them to maintain 12-14 on the Borg scale. This method ensures participants 
maintain a similar and consistent intensity of exercise despite the likelihood of participants having mixed 
fitness levels. 
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Table 2 Frailty Screening assessment methods and defined cut of points[92]  858 
Frailty Criteria  Assessment Method Cut-off for Frailty  
Unintentional 
Weight Loss  
Self-reported  ≥4.5 kg in the last year 
Muscle Weakness  Grip Strength (dominant hand) ≤18 kg 
Slow Gait Speed  Gait Speed over 13 meters  ≤0.8 m/s 
Exhaustion  Two questions from the Centre of 
Epidemiologic Studies Depression 
Scale [123]  
Answering “much or most of the time” 
to the questions “I felt that everything 
I did was an effort” and “I could not 
get going.”  
Low Levels of 
Activity  
Physical Activity Scale in the 
Elderly [124] 
≤56.4 
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Table 3 Summary of study outcomes.   878 
Assessment Methodology  Outcome  
Primary Outcome 
Habitual walking  Gait Speed (m/s) 
Secondary Outcomes 
Habitual walking  Temporal and spatial parameters 
Fast walking Temporal and spatial parameters 
Dual task walking  Temporal and spatial parameters 
Five times sit to stand  Seconds  
Spatial working test Spatial working memory (percentage score) 
Rey’s Auditory Verbal Learning Test Verbal memory (percentage score)  
Trail making Task Executive function (number of correct connections) 
Stroop test  Interference control (ms)  
Short form 36 questionnaire  Emotional role functioning, social role functioning, mental health, physical 
functioning, bodily pain, general health perceptions and physical role 
functioning 
Other Measures 
Whole blood fatty acids Fatty acid composition expressed as weight % of total fatty acids 
Enzyme-linked immunosorbent assay Serum homocysteine-bovine serum albumin (µg/ml) 
Community health activities program 
for seniors questionnaire  
Weekly caloric expenditure 
Three Day Diet Diary   Mean daily calorie (kcal), carbohydrate (g), protein (g) and fat(g) intake   
Omega-3 FFQ Dietary omega-3 PUFA intake 
National Adult Reading Test  Verbal intelligence 
 879 
